Introduction {#cei12940-sec-0001}
============

Naturally occurring CD4^+^CD25^high^CD127^low^forkhead box protein 3 (FoxP3^+^) regulatory T cells (T~reg~) constitute 5--10% of peripheral CD4^+^ T cells and maintain peripheral self‐tolerance in rodents and humans [1](#cei12940-bib-0001){ref-type="ref"}, [2](#cei12940-bib-0002){ref-type="ref"}. Functional impairment or quantitative deficiency of T~regs~ has been described in autoimmune liver diseases (AILD) [3](#cei12940-bib-0003){ref-type="ref"}, [4](#cei12940-bib-0004){ref-type="ref"}, including those targeted at bile ducts \[primary biliary cholangitis (PBC) [5](#cei12940-bib-0005){ref-type="ref"}, [6](#cei12940-bib-0006){ref-type="ref"} or primary sclerosing cholangitis (PSC)\] and hepatocytes \[autoimmune hepatitis (AIH)\] [3](#cei12940-bib-0003){ref-type="ref"}, [7](#cei12940-bib-0007){ref-type="ref"}, [8](#cei12940-bib-0008){ref-type="ref"}, [9](#cei12940-bib-0009){ref-type="ref"}. Current therapies for AILD are non‐curative, provide unsatisfactory control of hepatic inflammation and require long‐term immunosuppressive medications that carry unfavourable side effects. Thus, autologous T~reg~ therapy is an attractive option for the treatment of AILD that could provide long‐term immune‐regulation without daily medications and global immunosuppression.

T~reg~ survival and function is dependent upon interleukin (IL)−2 [10](#cei12940-bib-0010){ref-type="ref"}, which is required for the maintenance of effective levels of functional T~reg~ in autoimmune diseases [11](#cei12940-bib-0011){ref-type="ref"}, [12](#cei12940-bib-0012){ref-type="ref"}, [13](#cei12940-bib-0013){ref-type="ref"}. The importance of IL‐2 for T~reg~ function has not been studied closely in autoimmune liver diseases. The cell surface receptor for IL‐2 (IL‐2R) is composed of three subunits, alpha (IL‐2RA, CD25), beta (IL‐2RB, CD122) and common gamma (IL‐2RG, CD132). All leucocytes express IL‐2RG constitutively. Natural killer (NK), NK T cells (NK T) and memory CD8^+^ T cells also express IL‐2RB and T~reg~ express IL‐2RA constitutively. IL‐2RA is required for high‐affinity IL‐2 binding, while IL‐2RB and IL‐2RG transduce the IL‐2 signal [14](#cei12940-bib-0014){ref-type="ref"}. Two major signalling pathways conduct IL‐2‐induced responses: signalling from IL‐2RB leads to the activation of the serine/threonine kinase, AKT, and to up‐regulation of anti‐apoptotic molecules such as Bcl‐2, which is required for T cell survival [15](#cei12940-bib-0015){ref-type="ref"}. Signalling from IL‐2RG via Janus kinase 3 (JAK3) leads to signal transducer and activator of transcription‐5 (STAT‐5) activation [16](#cei12940-bib-0016){ref-type="ref"}, and is needed for T cell proliferation and differentiation and expression of anti‐apoptotic molecules [17](#cei12940-bib-0017){ref-type="ref"}, [18](#cei12940-bib-0018){ref-type="ref"}. Owing to their high levels of high‐affinity CD25, T~reg~ consume IL‐2 competitively, thereby maintaining their survival and function while suppressing bystander effector cells [19](#cei12940-bib-0019){ref-type="ref"}, [20](#cei12940-bib-0020){ref-type="ref"}. Where IL‐2 availability is low, such as in the inflamed hepatic microenvironment, T~reg~ function may be compromised and may be inadequate to counteract the activated immune infiltrate.

A number of studies have indicated that treatment with IL‐2 could improve immune‐mediated diseases. In rodents, type 1 diabetes mellitus could be prevented by *in‐vivo* IL‐2 administration [21](#cei12940-bib-0021){ref-type="ref"}, [22](#cei12940-bib-0022){ref-type="ref"}. In humans, low‐dose IL‐2 therapy enhanced T~reg~ frequencies and improved outcome in graft‐*versus*‐host disease, vasculitis and type 1 diabetes [11](#cei12940-bib-0011){ref-type="ref"}, [23](#cei12940-bib-0023){ref-type="ref"}, [24](#cei12940-bib-0024){ref-type="ref"}, [25](#cei12940-bib-0025){ref-type="ref"}. We recently reported very low levels of IL‐2 in the inflamed human liver [4](#cei12940-bib-0004){ref-type="ref"}. Thus, we considered that clinical grade IL‐2 (Proleukin) therapy might be effective in AILD.

In this study, we examined the effect of very low dose Proleukin (VLDP) on the biology of both peripheral and intrahepatic T~reg~, focusing upon regulatory phenotype and function. Successful T~reg~ therapy in AILD would require not only enhancing T~reg~ phenotype and function, but also recruitment of peripheral T~reg~ to the inflamed autoimmune livers. We demonstrate for the first time, to our knowledge, that VLDP selectively enhances T~reg~ STAT‐5 phosphorylation and subsequently up‐regulates functional molecules cytotoxic T lymphocyte antigen‐4 (CTLA‐4), CD25, FoxP3 and T~reg~ anti‐apoptosis marker Bcl‐2 in AILD. VLDP also maintains liver homing chemokine receptor CXCR3 expression on T~reg~. Importantly, VLDP enhances the suppressive function of T~reg~ via CTLA‐4, and anti‐CTLA‐4 can block this effect. Thus, we demonstrated both phenotype and mechanistic effects of VLDP on blood and intrahepatic T~reg~ from AILD patients suggesting that VLDP therapy may enhance immune‐regulatory restoration in AILD.

Materials and methods {#cei12940-sec-0002}
=====================

Ethics statement {#cei12940-sec-0003}
----------------

Written informed consent was obtained from all subjects in this study. Local Research Ethics Committees (LREC) and the University of Birmingham approved all experimental protocols (South Birmingham LREC reference: 98 CA/5192; Walsall LREC reference: 06/Q2708/11).

Blood and liver tissue {#cei12940-sec-0004}
----------------------

Venous blood, collected in ethylenediamine tetraacetic acid (EDTA) tubes, was obtained from healthy (control) individuals and individuals with AILD, including AIH, PBC and PSC. Explanted diseased liver tissue was obtained from patients undergoing liver transplantation for end‐stage AILD including PBC, PSC and AIH/PBC and AIH/PSC overlap diseases.

Isolation of liver infiltrating leucocytes (LIL) and peripheral blood mononuclear cells (PBMC) {#cei12940-sec-0005}
----------------------------------------------------------------------------------------------

LIL were isolated from fresh liver tissue. Briefly, explanted liver tissue was diced into 5 mm^3^ cubes, washed with phosphate‐buffered saline (PBS) and then homogenized in a Seward stomacher 400 circulator (260 rpm, 5 min). The homogenate was filtered through fine (63 μm) mesh (John Staniar and Co., Manchester, UK) and the lymphocytes isolated by density gradient separation using Lympholyte (VH Bio, Gateshead, UK) at 800 ***g*** for 20 min. The lymphocyte layer was collected and washed with PBS. Cell viability was assessed by trypan blue exclusion. Peripheral blood lymphocytes were isolated similarly from whole blood by density gradient separation using Lympholyte.

Culture of PBMC and LIL {#cei12940-sec-0006}
-----------------------

PBMC and LIL were cultured in 24‐well plates at a density of 1 × 10^6^ cells/ml in RPMI‐1640 with L‐glutamine medium containing penicillin (100 IU/ml), streptomycin (100 IU/ml), additional glutamine (2 mM) (G[ibco]{.smallcaps}, Carlsbad, CA, USA) and 10% human AB serum (TCS Biosciences, Buckingham, UK) and supplemented with 0 or 5 IU/ml Proleukin (Aldesleukin) (Novartis, Camberley, UK).

Surface phenotyping of freshly isolated intrahepatic and peripheral blood lymphocytes with or without Proleukin treatment {#cei12940-sec-0007}
-------------------------------------------------------------------------------------------------------------------------

Cell phenotypes were examined by flow cytometry. Dead cells were identified by staining with the Zombie NIR^TM^ fixable viability dye (BioLegend, San Diego, CA, USA) or e506 viability dye (eBioscience, San Diego, CA, USA) prior to staining with antibodies. To analyse expression of surface antigens, cells were incubated on ice for 30 min with antibodies against CD3, CD4, CD8, CD25, CD127 and markers of interest or isotype‐matched control antibodies in 2% fetal bovine serum (FBS) (Sigma Aldrich, Poole, UK) diluted in PBS. After washing with 2% FBS (Sigma Aldrich), cells were fixed for 10 min with 3% formaldehyde solution (Sigma Aldrich). To analyse expression of intracellular proteins, cells were fixed and stained using the FoxP3/transcription factor staining set (eBioscience), according to the manufacturer\'s instructions. Antibodies against surface markers (CD3, CD4, CD8 CD25, CD127) were generally added together with antibodies against intracellular markers of interest during the permeabilization and intracellular staining steps. Data were acquired using a CyAN ADP flow cytometer (Dako, Glostrup, Denmark). Single fluorophore‐labelled anti‐mouse immunoglobulin (Ig)Gκ/negative control (FBS) compensation particles (BD Biosciences, Franklin Lakes, NJ, USA) were used for compensation. Data were analysed offline using FlowJo (TreeStar Inc., Ashland, OR, USA).

The anti‐human antibodies used in flow cytometric analysis of marker expression included: anti‐CD3‐phycoerythrin‐cyanin 7 (PE‐Cy7) (SK7; BD Biosciences), anti‐CD4‐peridinin chlorophyll (PerCP/Cy5.5 (RPA‐T4; eBioscience), anti‐CD4‐Viogreen (VIT4; Miltenyi Biotec), anti‐CD8‐PE‐CF594 (RPA‐T8; BD Biosciences), anti‐CD25‐BV421 (M‐A251; BD Biosciences), anti‐CD45Ra‐allophycocyanin (APC)‐Vio770 (T6D11; Miltenyi Biotec), anti‐CD127‐fluorescein isothiocyanate (FITC) (eBioRDR5; eBioscience), anti‐CCR7‐PE‐CF594 (150503; BD Biosciences), anti‐granzyme B‐PE (GB11; eBioscience), anti‐CTLA‐4‐PE (BN13; BD Biosciences), anti‐Bcl‐2‐PE (100; BioLegend), anti‐FoxP3‐APC (PCH101; eBioscience) anti‐CD39‐PE (A1; eBioscience), anti‐T cell immunoglobulin and mucin domain‐containing‐3 (TIM3)‐PE (F38‐2E2; eBioscience), anti‐OX40‐PE (ACT35; BD Biosciences), anti‐CD69‐PE (FN50; Miltenyi Biotec), anti‐2B4‐PE (REA112; Miltenyi Biotec), anti‐CD73‐APC (AD2; eBioscience), anti‐CD137‐APC (4B4‐1; Miltenyi Biotec), anti‐glucocorticoid‐induced tumour necrosis factor receptor (GITR)‐APC (DT5D3; Miltenyi Biotec), anti‐lymphocyte‐activation gene 3 (LAG3)‐APC (3DS223H; eBioscience) and anti‐PD‐1‐APC (PD1.3.1.3; Miltenyi Biotec).

Analysis of STAT‐5 phosphorylation in response to IL‐2 {#cei12940-sec-0008}
------------------------------------------------------

To examine responsiveness of PBMC or LIL to IL‐2, cells in RPMI were stained with anti‐CD127‐FITC (eBioRDR5; eBioscience), anti‐CD20‐Viogreen (LT20; Miltenyi Biotec) and anti‐CD56‐pacific blue (HCD56; Biolegend) for 10 min at room temperature. Cells were then stimulated for 10 min at 37°C with Proleukin (0‐1000 IU/ml). Cells were fixed and permeabilized with BD Biosciences Phosflow buffers I and III according to the manufacturer\'s instructions then stained for 1 h at room temperature in 2% FBS (Sigma) with anti‐pSTAT‐5 (Y694)‐AlexaFluor 647 (47/STAT‐5), anti‐CD3‐PeCy7 (SK7), anti‐CD8‐PE‐CF594 (RPA‐T8) (all from BD Biosciences), anti‐CD4‐PerCPCy5.5 (RPA‐T4; eBioscience) and anti‐CD25‐PE (3G10; Miltenyi Biotec). All data were acquired using a CyAn ADP (Dako) flow cytometer and analysed using FlowJo (Tree Star) software.

Analysis of suppression of autologous T responder cell division by T~reg~ in response to IL‐2 {#cei12940-sec-0009}
---------------------------------------------------------------------------------------------

CD4^+^CD25^+^CD127^--^ T~reg~ and CD4^+^CD25^--^CD127^+^ responder T cells were isolated by flow sorting following prior enrichment of total CD4^+^ T cells from PBMC using magnetic negative selection (Biolegend). T~reg~ were cultured overnight with or without Proleukin (5 IU/ml). Responder T cells were labelled with cell trace violet (molecular probes; Thermofisher, Waltham, MA, USA) and cultured overnight without stimulation. Dendritic cells (DC) were derived from monocytes that were isolated from healthy donor PBMCs by magnetic negative selection (StemCell Technologies, Vancouver, Canada) and cultured for 5--7 days in IL‐4 (500 IU/ml; Miltenyi Biotec) and granulocyte--macrophage colony‐stimulating factor (GM‐CSF) (800 IU/ml; Berlex Laboratories, Richmond, CA, USA). DCs and T~reg~ were washed to remove cytokines and co‐cultured for 5 days with responder T cells in the presence of 0·5 μg/ml anti‐CD3 (clone OKT3; Biolegend) with or without 40 μg/ml anti‐CTLA‐4. Division of responder T cells under 50 μg/ml CTLA‐4‐Ig (abatacept) was also monitored. Cells were cultured at a ratio of 1 DC : 20 T cells with a 1 T~reg ~: 2·5 responder T cell ratio. At 5 days, cell trace violet dilution was measured by flow cytometry and the statistics percentage division and division index (the average number of cell divisions undergone by a cell in the original population) calculated using the FlowJo proliferation analysis platform.

Statistical analysis {#cei12940-sec-0010}
--------------------

Statistical significance between two variables across multiple subsets was tested by two‐way two‐tailed analysis of variance ([anova]{.smallcaps}) with Bonferroni\'s *post‐hoc* analysis. Significance between two populations was tested by paired *t*‐test and between multiple treatments by one way [anova]{.smallcaps} with Bonferroni\'s *post‐hoc* analysis. Analysis and graphical representation was performed using GraphPad Prism version 5 (GraphPad software, San Diego, CA, USA).

Results {#cei12940-sec-0011}
=======

Phosphorylation of STAT‐5 occurs selectively in T~reg~ at very low doses of Proleukin in normal blood {#cei12940-sec-0012}
-----------------------------------------------------------------------------------------------------

To analyse the responsiveness of different leucocyte populations to IL‐2 (Proleukin) and identify a dose that would phosphorylate STAT‐5 selectively in T~reg~, we administered Proleukin at doses of between 0 and 1000 IU/ml to PBMC from healthy control bloods and examined phosphorylation of STAT‐5 in T~reg~ and other leucocyte populations: (Fig. [1](#cei12940-fig-0001){ref-type="fig"}a and Supporting information, Fig. 1). With the exception of B cells, all cell types responded to Proleukin at 10 IU/ml and above (Fig. [1](#cei12940-fig-0001){ref-type="fig"}a). However, at 1 IU/ml, 25% of T~reg~ showed measurable pSTAT‐5 expression, while there was no up‐regulation in pSTAT‐5 in other subsets. More than 75% of T~reg~ demonstrated pSTAT‐5 induction at 10 IU/ml; however, this dose also led to phosphorylation of STAT‐5 in other CD4^+^ T cells and CD56^bright^ NK cells. Nevertheless, this pSTAT‐5 induction in non‐T~regs~ at this concentration was barely above baseline, as indicated by pSTAT‐5 median fluorescence intensity (MFI) (Fig. [1](#cei12940-fig-0001){ref-type="fig"}a). Most importantly, at 2--4 IU/ml, T~reg~ pSTAT‐5 MFI was 2·3--3·6‐fold above baseline, but there was no increase in pSTAT‐5 MFI for other subsets (Fig. [1](#cei12940-fig-0001){ref-type="fig"}a). Thus, we observed that with a very low dose of Proleukin (VLDP) (\< 5 IU/ml), selective phosphorylation of STAT‐5 in T~reg~ could be achieved. The characteristics of the control cohort used in these and subsequent phenotyping studies in this paper are given in Table [1](#cei12940-tbl-0001){ref-type="table-wrap"}.

![Very low dose interleukin (IL)−2 up‐regulates phosphorylated signal transducer and activator of transcription‐5 (pSTAT‐5) selectively in peripheral and liver‐infiltrating regulatory T cells (T~reg~) from patients with autoimmune liver disease. Peripheral blood mononuclear cells (PBMCs) from control bloods (a, *n* = 3) or autoimmune liver disease patient bloods \[b, autoimmune hepatitis (AIH) remission, *n* = 5; AIH relapse, *n *= 4; primary biliary cholangitis (PBC), *n* = 3; and primary sclerosing cholangitis (PSC), *n* = 3\] and liver‐infiltrating lymphocytes from explanted livers of patients with autoimmune liver disease (c, *n* = 4) were stimulated for 10 min with IL‐2 (Proleukin) at doses in the range 0--1000 IU/ml and the expression of p(Y694) STAT‐5 determined by flow cytometry for each leucocyte population. Graphs summarize pSTAT‐5 expression, quoted as percentage of positive cells or median fluorescence intensity (MFI). Data are mean ± standard error of the mean (s.e.m.).](CEI-188-394-g001){#cei12940-fig-0001}

###### 

Demographic, laboratory, histology and treatment details of patients in the peripheral blood cohort

  Disease   Age (years)   Sex   BR   AST    ALT   ALP    Na+   CR    IgM    IgG     INR    UKELD   Histology                                                   Treatment
  --------- ------------- ----- ---- ------ ----- ------ ----- ----- ------ ------- ------ ------- ----------------------------------------------------------- ------------------------------------------
  AIH F     28            M     19   78     23    65     139   68    0·6    17      1·2    49      Moderate hepatitis, established cirrhosis                   Azathioprine + tacrolimus + prednisolone
  AIH F     61            F     10   129    125   120    139   71    0·5    25      1·2    47      Moderate‐ severe activity, F4                               Mycophenolate
  AIH F     57            F     15   76     53    114    140   61    1·4    18      1·1    48      Moderate hepatitis, F3                                      Azathioprine + prednisolone
  AIH F     42            M     37   68     120   104    142   86    1·3    17      1·0    49      Moderate hepatitis, established cirrhosis                   Azathioprine, prednisolone
  AIH F     64            M     7    72     127   93     141   87    0·7    17      1·0    45      Moderate lobular hepatitis, F2                              Mycophenolate + prednisolone
  AIH F     24            M     59   167    253   120    138   49    0·7    21      1·2    53      Moderate hepatitis, F3                                      Mycophenolate + prednisolone
  AIH R     58            M     19   42     30    82     142   86    1      16      0·9    47      Moderate lobular inflammatory activity, F2                  Azathioprine
  AIH R     46            F     4    17     8     76     137   67    1·2    13      1·0    44      Mild hepatitis, F2                                          Azathioprine
  AIH R     51            F     11   26     21    58     143   72    1      10      1·0    45      Quiescent AIH, cirrhotic                                    None
  AIH R     58            F     15   39     40    90     144   58    0·7    12      1·1    45      Quiescent AIH, F1                                           Azathioprine + prednisolone
  AIH R     45            F     10   16     11    86     142   67    0·9    9       1·0    45      Mild hepatitis, F1                                          Azathioprine
  AIH R     35            F     14   22     19    75     139   58    1      11      1·1    48      Moderate hepatitis, F3                                      Azathioprine
  AIH R     54            F     7    21     28    76     143   66    1·2    9       1·0    43      Moderate hepatitis, F3                                      Mycophenolate + prednisolone
  AIH R     45            F     13   43     36    84     138   64    1      20      1·0    47      Mild hepatitis, F2                                          Azathioprine
  AIH R     21            F     17   30     35    70     143   63    1      8       1·0    46      Mild hepatitis, Established cirrhosis                       Azathioprine + prednisolone
  AIH R     57            F     3    25     28    65     142   82    0·8    12      1·0    42      Mild hepatitis, F2                                          Mycophenolate + prednisolone
  AIH R     33            F     7    28     24    46     139   65    0·6    11      1·0    46      Mild lobular, hepatitis, F2                                 Mycophenolate + prednisolone
  AIH R     51            F     8    33     33    93     140   60    1·3    12      1·0    46      Mild hepatitis, F1                                          Mycophenolate + prednisolone
  AIH R     36            M     11   18     22    67     141   58    0·8    14      1·2    45      Mild hepatitis, established cirrhosis                       Azathioprine
  AIH R     21            F     11   17     19    67     141   61    0·8    8       1·0    46      Mild hepatitis, F1                                          Mercaptopurine
  PBC       72            F     8    36     34    210    144   105   2·9                                                                                       
  PBC       63            F     5    32     20    160    141   83    3·5    9·37    0·9    43      Non‐cirrhotic                                               Ursodeoxycholic acid
  PBC       51            F     39   113    76    184    142   93    5·6    16·81   1·1    49      Non‐cirrhotic                                               Ursodeoxycholic acid
  PBC       47            M     13   n.a.   32    220    140   88    6·6    24·88   1·0    47      Chronic biliary disease, paucity of bile ducts, cirrhosis   Ursodeoxycholic acid
  PBC       63            F     5    32     20    160    141   83    3·5    9·37    0·9    43      Non‐cirrhotic                                               UDCA
  PBC       51            F     39   113    76    184    142   93    5·6    16·81   1·1    49      Non cirrhotic                                               UDCA
  PBC       47            F     13   29     21    150    142   52    1·71   10·64   1·1    46      2007 ‐ PBC with FNH; no cirrhosis                           UDCA
  PBC       58            F     11   n.a.   88    653    138   66    7·15   23·63   1·0    47      n.a.                                                        UDCA
  PBC       41            F     5    20     23    74     145   68    1·31   12·75   1·1    42      n.a.                                                        UDCA
  PBC       47            F     32   112    129   446    139   57    7·78   13·32   1·0    50      n.a.                                                        UDCA
  PSC       54            F     4    14     19    297    142   78    0·6    9       0·8    42      PSC, F2                                                     UDCA
  PSC       43            M     70   151    68    575    139   60    0·8    25      1·2    54      PSC cirrhotic                                               UDCA
  PSC       77            M     3    21     10    64     136   118   0·6    10      0·9    45      PSC, F2                                                     UDCA
  Control   45            M     8    12     18    n.a.   133   69    n.a.   n.a.    0·9    49      n.a.                                                        None
  Control   56            F     4    8      20    n.a.   140   74    n.a.   17·07   1·0    43      n.a.                                                        None
  Control   60            M     10   41     55    n.a.   145   105   n.a.   15·75   1·1    44      n.a.                                                        None
  Control   49            M     18   16     13    n.a.   141   85    n.a.   10·11   1·1    48      n.a.                                                        None
  Control   60            M     3    12     16    n.a.   139   76    n.a.   N/A     n.a.   n.a.    n.a.                                                        None
  Control   67            F     9    33     28    n.a.   140   64    n.a.   n.a.    1·1    46      n.a.                                                        None
  Control   42            M     6    24     21    n.a.   135   72    n.a.   n.a.    n.a.   n.a.    n.a.                                                        None
  Control   76            M     6    32     27    n.a.   143   79    n.a.   12·71   n.a.   n.a.    n.a.                                                        None
  Control   41            M     63   26     12    n.a.   140   93    n.a.   9·19    n.a.   n.a.    n.a.                                                        None

AIH R = autoimmune hepatitis in remission; AIH F = autoimmune hepatitis in flare up/relapse; PSC = primary sclerosing cholangitis; PBC = primary biliary cholangitis; AST = aspartate transaminase; ALT = alanine transaminase; ALP = alkaline phosphatase BR = bilirubin; Na+ = sodium; CR = creatinine; UKELD = United Kingdom End Stage Liver Disease Scoring; UDCA = ursodeoxycholic acid; n.a. = not available.

Very low doses of Proleukin induce selective phosphorylation of STAT‐5 in intrahepatic and peripheral blood T~reg~ of patients with autoimmune liver diseases {#cei12940-sec-0013}
-------------------------------------------------------------------------------------------------------------------------------------------------------------

PBMC from AIH, PBC and PSC patients were treated with Proleukin in the range of 0--100 IU/ml. Similar to controls, T~reg~ of AIH patients \[both remission and flare‐up (relapse)\], PBC patients and PSC patients demonstrated a selective pSTAT‐5 induction at doses below 10 IU/ml, especially at 5 IU/ml (Fig. [1](#cei12940-fig-0001){ref-type="fig"}b and Supporting information, Fig. 2). We then treated human LIL isolated from explanted autoimmune liver disease tissues with 0--100 IU/ml Proleukin, and again selective pSTAT‐5 enhanced induction was seen in T~reg~ at doses below 10 IU/ml (Fig. [1](#cei12940-fig-0001){ref-type="fig"}c). Descriptions of all AILD blood and liver explant donors whose PBMC and LIL were used in these and subsequent studies in this paper to address the effect of IL‐2 on phenotype are given in Tables [1](#cei12940-tbl-0001){ref-type="table-wrap"} and [2](#cei12940-tbl-0002){ref-type="table-wrap"} \[blood donors were: AIH = 20 (aged 44·4 ± 13·8 years, disease in remission = 14, disease in flare up/relapse = 6); PSC = 3 (aged 58·0 ± 17·3 years); PBC = 10 (aged 54·0 ± 9·6 years); control = 9 (aged 55·1 ± 11·9 years)\]. Liver donors were: PBC = 5 (aged 59·4 ± 6·4 years); PSC = 2 (aged 51·5 ± 23·3 years); AIH overlap = 2 (aged 38·0 ± 24·0 years), PBC/AIH overlap = 1; and PSC/AIH overlap = 1).

###### 

Demographic, histology and treatment details of patients in the liver explant cohort

  Disease           Age (years)   Sex   Explant history         Treatment before transplantation
  ----------------- ------------- ----- ----------------------- ----------------------------------
  PBC               51            M     Moderate fibrosis       Ursodeoxycholic acid
  PBC               63            F     Established cirrhosis   Ursodeoxycholic acid
  PBC               65            F     Established cirrhosis   Ursodeoxycholic acid
  PBC               64            F     Established cirrhosis   Ursodeoxycholic acid
  PBC               54            F     Established cirrhosis   Ursodeoxycholic acid
  PSC               68            M     Established cirrhosis   
  PSC               35            M     Established cirrhosis   
  PBC/AIH overlap   55            F     Established cirrhosis   Ursodeoxycholic acid
  PSC/AIH overlap   21            F     Established cirrhosis   

AIH = autoimmune hepatitis; PBC = primary biliary cholangitis; PSC = primary sclerosing cholangitis.

Very low doses of Proleukin induce T~reg~ functional markers CTLA‐4, CD25 and FoxP3 selectively in both blood and intrahepatic T~reg~ {#cei12940-sec-0014}
-------------------------------------------------------------------------------------------------------------------------------------

Having found 5 IU/ml Proleukin by dose titration to be the optimal concentration to induce a selective STAT‐5 response in blood and liver T~reg~ of AILD patients, we determined the effect of 5 IU/ml Proleukin on T cell phenotype and function. PBMC and LIL from AILD patients were exposed to 0 IU/ml or 5 IU/ml Proleukin for 18 h and effects on markers of T cell activation and T~reg~ function by T cell subsets were assessed; 5 IU/ml Proleukin increased significantly the levels of CD25, CTLA‐4 and FoxP3 on peripheral blood T~reg~ of AILD patients (Fig. [2](#cei12940-fig-0002){ref-type="fig"}a and Supporting information, Fig. 3). In liver, basal expressions of CTLA‐4, CD25 and FoxP3 on T~reg~ were higher than in blood and similar to those observed in blood following Proleukin exposure (Fig. [2](#cei12940-fig-0002){ref-type="fig"}a). There were clear trends towards increased expression of the T~reg~ markers CD25 and FoxP3 with VLDP in liver T~reg~ from PBC, PSC and AIH, supporting potentiation of T~reg~ in the liver in settings of the AILDs (Fig. [2](#cei12940-fig-0002){ref-type="fig"}a and Supporting information, Fig. 3). These observations are consistent with and also reflective of upstream pSTAT‐5 induction by VLDP in liver T~reg~ (Fig. [1](#cei12940-fig-0001){ref-type="fig"}c). Frequencies of expression of CD25, CTLA‐4 and FoxP3 were largely not altered in blood or liver T~reg~ by VLDP (Supporting information, Fig. 4).

![Effect of very low dose interleukin (IL)−2 on expression of IL‐2‐regulated regulatory T cells (T~reg~) functional markers CD25, cytotoxic T lymphocyte antigen‐4 (CTLA‐4) and forkhead box protein 3 (FoxP3) by T~reg~ cells from blood and liver. Peripheral blood mononuclear cells (PBMCs) from patients with autoimmune hepatitis (AIH) (*n* = 5), primary sclerosing cholangitis (PSC), (*n* = 3) and primary biliary cholangitis (PBC), *n* = 6) and liver‐infiltrating leucocytes from autoimmune liver diseases (AILD) livers were exposed to 0 or 5 IU/ml IL‐2 (Proleukin) for 18 h and the median fluorescence intensity of CD25, CTLA‐4 and FoxP3 examined by flow cytometry for (a) CD4, CD8 and T~reg~ cells and (b) CD4 subsets defined by CD25 *versus* CD127 expression. Data are mean ± standard error of the mean (s.e.m.). Significant effects of IL‐2 analysed by paired *t*‐tests (a) and two‐way analysis of variance ([anova]{.smallcaps}) with Bonferroni\'s *post‐hoc* test (b) are shown.](CEI-188-394-g002){#cei12940-fig-0002}

Because we noticed that 18 h exposure to Proleukin led to STAT‐5 phosphorylation in CD25^+^CD127^+^CD4^+^ T cells that mirrored that in T~reg~ (CD25^+^CD127^--^CD4^+^) (both frequency and MFI) (Supporting information, Fig. 5), we evaluated the effect of 18‐h VLDP on the expression of CD25, CTLA‐4 and FoxP3 by the CD25^+^CD127^+^CD4^+^ T effector cell population in the blood of AILD patients (Fig. [2](#cei12940-fig-0002){ref-type="fig"}b). Importantly, despite phosphorylation of STAT‐5, this subset, unlike T~reg~, did not up‐regulate CD25, CTLA4 or FoxP3 (Fig. [2](#cei12940-fig-0002){ref-type="fig"}b).

We then investigated the effect of VLDP on the expression by peripheral and liver‐infiltrating T~reg~ of tumour necrosis factor (TNF) receptor superfamily members CD137, OX40 and GITR. Culture in 5 IU/ml Proleukin helped to maintain expression frequencies of CD137 and GITR on peripheral T~reg~ over 18 h and promoted an increase in the frequency of OX40 expressing peripheral T~reg~ (Fig. [3](#cei12940-fig-0003){ref-type="fig"}a and Supporting information, Fig. 3). Exposure to VLDP did not influence the frequency of expression of these markers on liver‐infiltrating T~reg~ (Fig. [3](#cei12940-fig-0003){ref-type="fig"}a). We also investigated the impact of VLDP on T~reg~‐associated surface markers, including CD39, CD73 and LAG3. Proleukin 5 IU/ml had no effect on the expression frequency of any of these molecules (Fig. [3](#cei12940-fig-0003){ref-type="fig"}b and Supporting information, Fig. 3): high expression of CD39 was maintained, CD73 remained low‐expressed and TIM3 and LAG3, which were not detected at baseline, were not induced by Proleukin treatment on T~reg~. Also, VLDP did not alter expression of the activation marker, CD69 or the immune checkpoint and programmed cell death receptor‐1 (PD‐1) on CD4^+^ or CD8^+^ T cells or T~reg~ (Fig. [3](#cei12940-fig-0003){ref-type="fig"}c and Supporting information, Fig. 3). Consistent with a lack of pSTAT‐5 induction in CD8^+^ T cells under VLDP, 5 IU/ml Proleukin did not affect expression of granzyme B or activation marker 2B4 by CD8^+^ T cells (Fig. [3](#cei12940-fig-0003){ref-type="fig"}c and Supporting information, Fig. 3).

![(a--c) Effect of very low dose interleukin (IL)−2 on regulatory T cells (T~reg~) and T effector functional and activation phenotypes. Peripheral blood mononuclear cells (PBMCs) from patients with autoimmune hepatitis (AIH) and liver infiltrating leucocytes from autoimmune liver diseases (AILD) livers were exposed to 0 or 5 IU/ml IL‐2 (Proleukin) for 18 h and the expression of functional and activation markers by T cell subsets analysed by flow cytometry. (a) Expression of tumour necrosis factor (TNF) receptor superfamily members by blood and liver T~reg~. (b) Expression of CD39, CD73, T cell immunoglobulin and mucin domain‐containing‐3 (TIM3) and lymphocyte‐activation gene 3 (LAG3) by blood T~reg~. (C) Expression of CD69, programed death 1 (PD‐1), 2B4 and granzyme B by blood CD4, CD8 and T~reg~. Data are mean ± standard error of the mean (s.e.m.) for 2--6 donors. (d--f) Very low dose IL‐2 increases T~reg~ suppressive ability in a mechanism involving cytotoxic T lymphocyte antigen‐4 (CTLA‐4). CD4^+^CD25^+^CD127^--^ T~reg~ and autologous CD4^+^CD25^--^ T responder cells were isolated from PBMC of control individuals. T responders were labelled with cell trace violet and following overnight exposure of T~reg~ to 0 or 5 IU/ml Proleukin were co‐cultured with the T~reg~ in the presence of anti‐CD3 and dendritic cells, with or without CTLA‐4 blockade. Cell trace violet dilution indicating T responder cell division was analysed by flow cytometry at 5 days. (d) Representative flow cytometry histograms of T responder division showing percentage division. (e) Division index summary data (*n* = 3) of T responders in the presence of T~reg~ pretreated with 0 or 5 IU/ml Proleukin. (f) Division index summary data (*n* = 3) of T responders in the presence of T~reg~ pretreated with 0 or 5 IU/ml Proleukin with or without anti‐CTLA‐4. Data are mean ± standard error of the mean (s.e.m.). Significant effects of IL‐2 and CTLA‐4 blockade analysed by paired *t*‐tests (e) and one‐way analysis of variance ([anova]{.smallcaps}) with Bonferroni *post‐hoc* test (f) are shown.](CEI-188-394-g003){#cei12940-fig-0003}

Very low dose Proleukin enhances T~reg~ suppressive potential in a CTLA‐4‐dependent manner across all autoimmune liver diseases {#cei12940-sec-0015}
-------------------------------------------------------------------------------------------------------------------------------

Having established that VLDP 5 IU/ml enhances T~reg~ expression of regulatory functional molecules we sought to verify that these changes in phenotype associate with improvements in T~reg~ function. We tested whether exposure to VLDP could increase the ability of T~reg~ to suppress the division of autologous CD25^--^CD4^+^ T effector cells. We used a system of anti‐CD3 together with monocyte‐derived DC to supply co‐stimulatory ligands. This system was chosen over conventional anti‐CD3/CD28 bead activation of T cell proliferation in order that the functional impact of antigen‐presenting cell--T~reg~ contact‐dependent mechanisms of suppression such as involving CTLA‐4 might be studied. Pre‐treatment of T~reg~ with Proleukin reduced significantly the division of T responder cells from control individuals cultured 2·5 : 1 with autologous T~reg~ (Fig. [3](#cei12940-fig-0003){ref-type="fig"}d,e). This elevated suppressive potential of VLDP‐treated T~reg~ was overcome in the presence of anti‐CTLA‐4 (Fig. [3](#cei12940-fig-0003){ref-type="fig"}d,f). Consistent with our observations that CTLA‐4‐Ig can reduce T responder division (Supporting information, Fig. 6a), anti‐CTLA‐4 also tended to increase T responder division in the presence of untreated T~reg~ (Fig. [3](#cei12940-fig-0003){ref-type="fig"}f). We observed the same trends of improved T~reg~ function involving contribution from CTLA‐4 with VLDP treatment of T~reg~ in both cases of AILD patients tested (Supporting information, Fig. 6b).

Very low dose Proleukin treatment does not alter liver homing CXCR3 expression by peripheral blood T~reg~ in autoimmune liver diseases {#cei12940-sec-0016}
--------------------------------------------------------------------------------------------------------------------------------------

Regulatory T cell homing to the site of liver inflammation is crucial for the success of T~reg~ therapies, thus we examined the crucial liver‐homing chemokine receptor, CXCR3, on blood T~reg~ of autoimmune liver disease patients. *De‐novo* expression levels (MFI and frequency) of CXCR3 were similar in patients with AIH compared to controls (Fig. [4](#cei12940-fig-0004){ref-type="fig"}a). Importantly, VLDP 5 IU/ml did not have any impact upon CXCR3 expression in AIH patients over 18 h or up to 3 days (Fig. [4](#cei12940-fig-0004){ref-type="fig"}b,c). Peripheral T~reg~ from PSC and PBC patients also showed no change in their CXCR3 expression with sustained culture in VLDP (Fig. [4](#cei12940-fig-0004){ref-type="fig"}b,d), thus VLDP therapy may be applicable for all three autoimmune liver diseases without impairing the recruitment capacity of T~reg~.

![Very low dose interleukin (IL)−2 does not down‐regulate liver‐homing CXCR3 receptor on regulatory T cells (T~reg~). (a) Peripheral blood mononuclear cells (PBMCs) were isolated from controls and autoimmune hepatitis (AIH) patients and T~reg~ phenotyped for CXCR3 by flow cytometry *ex vivo*. (b,c) CXCR3 expression was measured in PBMC T~reg~ from patients with AIH, primary sclerosing cholangitis (PSC) or primary biliary cholangitis (PBC) *ex vivo* and after culture for 18 h and/or 3 days in 5 IU/ml IL‐2 (Proleukin). Expression of CXCR3 by CD4^+^CD25^+^CD127^--^ T~reg~ of one representative donor from each disease cohort is shown in (b) and expression summarized for AIH, PSC donors and PBC donors in (c). Data are mean ± standard error of the mean (s.e.m.).](CEI-188-394-g004){#cei12940-fig-0004}

Very low dose Proleukin treatment increases total T~reg~ frequencies and promotes the strongest T~reg~ suppressive phenotype in the CD45RA^--^CCR7^--^ population of T~reg~ {#cei12940-sec-0017}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We noted that the CD25^+^CD127^--^FoxP3^+^ T~reg~ population, as a proportion of total CD4^+^ T cells, increased significantly with culture in VLDP up to 3 days in AILD patients and controls (Fig. [5](#cei12940-fig-0005){ref-type="fig"}a). No differences in frequency were seen between any of the patient or control groups at either condition. The naive (CD45RA^+^CCR7^+^) subset of T~reg~ has been reported to maintain the T~reg~‐specific demethylated region (TSDR) following expansion, making them an attractive option for T~reg~ cell immunotherapy [26](#cei12940-bib-0026){ref-type="ref"}, [27](#cei12940-bib-0027){ref-type="ref"}; thus, we evaluated the effect of 3 days VLDP on frequencies of each of the maturation subsets of CD25^+^CD127^--^FoxP3^+^ T~reg~ defined by CD45RA and CCR7 expression [28](#cei12940-bib-0028){ref-type="ref"}. VLDP did not alter the proportions of the maturation subsets in any AILD patient cohorts (AIH, PSC, PBC) or controls (Fig. [5](#cei12940-fig-0005){ref-type="fig"}b,c). None the less, as before, VLDP increased significantly the expression of IL‐2 regulated markers CTLA‐4, CD25 and FoxP3 on T~reg~ from all subsets. Overall, across AIH, PSC, PBC and control, the effector memory (CD45RA^--^CCR7^--^) subset of CD25^+^CD127^--^FoxP3^+^ T~reg~ cells showed the greatest induction of T~reg~ functional markers with VLDP treatment (Fig. [5](#cei12940-fig-0005){ref-type="fig"}d).

![Low dose Proleukin treatment increases total regulatory T cell (T~reg~) frequencies and promotes the strongest T~reg~ phenotype in the CD45Ra^--^CCR7^--^ effector memory population of T~reg~. (a) Peripheral blood mononuclear cells (PBMCs) from controls, autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) patients were exposed to 0 or 5 IU/ml IL‐2 (Proleukin) for 3 days and the frequency of CD4^+^CD25^+^CD127^--^forkhead box protein 3 (FoxP3)^+^ T~reg~ assessed by flow cytometry. Significant effects of IL‐2 were analysed by two‐way analysis of variance ([anova]{.smallcaps}) with Bonferroni\'s *post‐hoc* analysis. Frequencies of memory and naive subsets of CD4^+^CD25^+^CD127^--^FoxP3^+^ T~reg~ as defined by CD45Ra and CCR7 expression were also determined at 3 days by flow cytometry. (b) Representative flow cytometry density plot of CCR7 *versus* CD45Ra for one PSC donor after 3 days of culture in 0 or 5 IU/ml Proleukin and summary data for all donors (c). Significant effects of IL‐2 on the frequencies of the different memory/naive subsets were compared by two‐way [anova]{.smallcaps} with Bonferroni\'s *post‐hoc* analysis, but no significant differences were identified. (D) Expression of cytotoxic T lymphocyte antigen‐4 (CTLA‐4), CD25 and FoxP3 by each memory or naive subset of T~reg~. Data are mean ± standard error of the mean (s.e.m.) (control (*n* = 3), AIH (*n* = 4), PSC (*n* = 3) and PBC (*n* = 6), central memory (CM) (CD45Ra^--^CCR7^+^); naive (CD45Ra^+^CCR7^+^); terminally differentiated effector memory (TEMRA) (CD45Ra^+^CCR7^--^); effector memory (EM) (CD45Ra^--^CCR7^--^). Effects of 5 IU/ml Proleukin on the expression of these markers by each subset were analysed by two‐way [anova]{.smallcaps} with Bonferroni\'s *post‐hoc* tests. Stars indicate where there was a significant effect of IL‐2 upon the expression of the marker by the subset (\**P* \< 0·05; \*\**P* \< 0·01; \*\*\**P* \< 0·001; \*\*\*\**P* \< 0·0001). Braces with stated *P*‐values indicate significant differences in expression by the subsets under 5 IU/ml Proleukin conditions. With the exception of CTLA‐4 expression by naive *versus* EM cells in PSC patients, or of FoxP3 expression by CN *versus* naive, CM *versus* TEMRA or TEMRA *versus* effector memory in PBC patients, there were no significant differences between the subsets for expression of any marker in the absence of IL‐2 treatment.](CEI-188-394-g005){#cei12940-fig-0005}

Liver‐infiltrated T~reg~ are restricted predominantly to the CD45RA^--^CCR7^--^ population {#cei12940-sec-0018}
------------------------------------------------------------------------------------------

Blood CD25^+^CD127^--^FoxP3^+^ T~reg~ subsets in AILD patients are comprised of approximately 60% effector memory (CD45RA^--^CCR7^--^), 15--20% central memory (CD45RA^--^CCR7^+^) and 15--20% naive (CD45RA^+^CCR7^+^) populations. Because VLDP increased significantly the expression of T~reg~ functional markers CTLA‐4, CD25 and FoxP3, especially in the CD45RA^--^CCR7^--^ subset of T~reg~, we investigated the frequency of these subsets in the inflamed human liver. We found that the effector memory CD45RA^--^CCR7^--^ subset of CD25^+^CD127^--^FoxP3^+^ T~reg~ population is increased significantly (95%) in the inflamed human livers compared to peripheral blood (60%) (Fig. [6](#cei12940-fig-0006){ref-type="fig"}a,b).

![Comparison of the frequencies of memory and naive regulatory T cell (T~reg~) populations in blood and liver. (a) Frequencies of memory and naive subsets of CD4^+^CD25^+^CD127^--^ T~reg~ as defined by CD45Ra and CCR7 expression were determined by flow cytometry for peripheral blood mononuclear cells (PBMCs) and liver infiltrating lymphocytes from patients with autoimmune liver diseases (AILD). (a) Representative flow cytometry density plot for expression of CD45Ra and CCR7 by blood and liver infiltrating T~reg~ showing the four subsets including: central memory (CM) (CD45Ra^--^CCR7^+^); naive (CD45Ra^+^CCR7^+^); terminally differentiated effector memory (TEMRA) (CD45Ra^+^CCR7^--^); effector memory (EM) (CD45Ra^--^CCR7^--^). (b) Summary frequencies for each memory and naive subset in blood \[*n* = 6 donors with autoimmune hepatitis (AIH)\] and liver \[*n* = 4 donors with AILDs including primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC)\]. Data are mean ± standard error of the mean (s.e.m.). Significance was tested by non‐matched two‐way analysis of variance ([anova]{.smallcaps}) and showed significant interaction for subset *versus* tissue *P* \< 0·0001. Bonferroni\'s *post‐hoc* tests identified significant differences between blood and liver in the frequencies of CM and EM cells, as indicated. There was no significant effect of tissue on subset distribution but there was a significant effect of subset *P* \< 0·0001.](CEI-188-394-g006){#cei12940-fig-0006}

Very low dose Proleukin up‐regulates expression of the anti‐apoptotic molecule Bcl‐2 on T~reg~ compared to effector T cells {#cei12940-sec-0019}
---------------------------------------------------------------------------------------------------------------------------

The anti‐apoptotic protein Bcl‐2 is regulated differentially in effector T cells *versus* T~reg~ [29](#cei12940-bib-0029){ref-type="ref"}. To assess whether VLDP alters Bcl‐2 expression, lymphocytes from AILD patients and controls were treated with 5 IU/ml Proleukin for 18 h or 3 days and their Bcl‐2 expression was evaluated. While expression by total CD4^+^ and CD8^+^ T cells was not altered up to 3 days, VLDP tended to increase blood T~reg~ expression of Bcl‐2 by 18 h (Fig. [7](#cei12940-fig-0007){ref-type="fig"}a). By 3 days, a significant twofold up‐regulation of Bcl‐2 expression in T~reg~ of patients with AIH was seen (Fig. [7](#cei12940-fig-0007){ref-type="fig"}b), and the same trend was observed in PSC and PBC (Fig. [7](#cei12940-fig-0007){ref-type="fig"}c). We also verified the effect of VLDP on Bcl‐2 in AILD liver T~reg~ at 3 days. Consistent with the response found in blood, we observed selective up‐regulation of Bcl‐2 in liver T~reg~ (Fig. [7](#cei12940-fig-0007){ref-type="fig"}d), which were of PBC and PSC disease backgrounds. In view of the STAT‐5 response by the CD4^+^CD25^+^CD127^+^ subset with sustained exposure to VLDP, we analysed the effect of VLDP on Bcl‐2 expression by each CD4^+^ T cell subset, defined by CD25 *versus* CD127 expression at 3 days in blood (Fig. [7](#cei12940-fig-0007){ref-type="fig"}e,f) and liver (Fig. [7](#cei12940-fig-0007){ref-type="fig"}g), and saw that in blood the CD4^+^CD25^+^CD127^+^ subset also showed increased Bcl‐2 expression with Proleukin; however, the relative fold increase in Bcl‐2 expression by this effector subset was less compared to that observed for T~reg~.

![Very low dose interleukin (IL)‐2 up‐regulates Bcl‐2 expression in regulatory T cells (T~reg~) from blood and liver. Peripheral blood mononuclear cells (PBMCs) from autoimmune hepatitis (AIH) patients (a,b,e), primary sclerosing cholangitis (PSC) patients (c,f), primary biliary cholangitis (PBC) patients (c,f) and liver‐infiltrating lymphocytes from autoimmune liver diseases (AILD) livers (d,g) were exposed to 0 or 5 IU/ml IL‐2 (Proleukin) for 18 h (a) or 3 days (b--g) and the median fluorescence intensity (MFI) of Bcl‐2 on CD4, CD8 and T~reg~ examined by flow cytometry (a--d). (E--G) Day 3 Bcl‐2 expression by blood (e,f) and liver (g) CD4^+^ T cell subsets defined by CD25 *versus* CD127 expression. Data are mean ± standard error of the mean (s.e.m.). Significant effects of IL‐2 were assessed by paired *t*‐tests (a--d) and two‐way analysis of variance ([anova]{.smallcaps}) (e--g).](CEI-188-394-g007){#cei12940-fig-0007}

Discussion {#cei12940-sec-0020}
==========

IL‐2 is a crucial cytokine for survival and function of T cells, including T~reg~. We demonstrated in this study that very low dose clinical grade IL‐2 (Proleukin) induces STAT‐5 phosphorylation selectively in CD4^+^CD25^+^CD127^--^ T~reg~ from blood and liver of patients with AILD and is accompanied not only by a series of phenotypic and functional changes, but also up‐regulates Bcl‐2 to support T~reg~ survival. These data support existing evidence in autoimmune conditions such as diabetes and vasculitis that VLDIL‐2 administration contributes to the maintenance of self‐tolerance by increasing T~reg~ frequency [23](#cei12940-bib-0023){ref-type="ref"}, [25](#cei12940-bib-0025){ref-type="ref"}, [30](#cei12940-bib-0030){ref-type="ref"}. Our study extends the potential of VLDP therapy to the treatment of autoimmune liver diseases.

Administration of the IL‐2 or the IL‐2 : anti‐IL‐2 monoclonal antibody complex reduces autoimmune disease in rodent models [31](#cei12940-bib-0031){ref-type="ref"}, [32](#cei12940-bib-0032){ref-type="ref"}. Studies in vasculitis, graft‐*versus*‐host disease, systemic lupus erythematosus and type 1 diabetes suggest that an IL‐2 dose range of 0·3--3·0 × 10^6^ IU/m^2^ is well tolerated, and achieves a preferential increase in the percentage of T~reg~ with no induction of effector T cell activation [23](#cei12940-bib-0023){ref-type="ref"}, [25](#cei12940-bib-0025){ref-type="ref"}, [33](#cei12940-bib-0033){ref-type="ref"}, [34](#cei12940-bib-0034){ref-type="ref"}. The dose range we have identified working with clinical grade IL‐2 (Proleukin) *in vitro* is similar to other investigators, who have applied VLDP in autoimmune diseases [11](#cei12940-bib-0011){ref-type="ref"}, [23](#cei12940-bib-0023){ref-type="ref"}, [25](#cei12940-bib-0025){ref-type="ref"}, [34](#cei12940-bib-0034){ref-type="ref"}. High‐dose IL‐2 is approved in cancer therapy, where it promotes tumour killing by activating NK cells and CD4^+^ and CD8^+^ effector T cells [12](#cei12940-bib-0012){ref-type="ref"}; however, pulmonary vascular leakage occurs as a side effect to this treatment [35](#cei12940-bib-0035){ref-type="ref"}. By avoiding the activation of effector cells, VLDP should be safe for clinical application in general. Indeed, a former dose escalation study of low‐dose IL‐2 for treatment of graft‐*versus*‐host disease reported very few adverse events except skin induration in a minority of study patients. Other potentially linked rare side effects include fatigue, malaise, fever, thrombocytopenia and raised serum creatinine [23](#cei12940-bib-0023){ref-type="ref"}. Despite this, it is prudent that low‐dose Proleukin therapy in a hospital setting be restricted to patients with normal cardiac and pulmonary function.

IL‐2 is crucial for T~reg~ function. Binding of IL‐2 to IL‐2RA (CD25) on T~reg~ leads to phosphorylation of STAT‐5, resulting in up‐regulation of FoxP3 [36](#cei12940-bib-0036){ref-type="ref"} and functional surface markers. FoxP3 is essential for T~reg~ development and function, as evident from the occurrence of immunodysregulation polyendocrinopathy enteropathy X‐linked (IPEX) syndrome in patients with mutations in FoxP3 [37](#cei12940-bib-0037){ref-type="ref"}, [38](#cei12940-bib-0038){ref-type="ref"}. Although T~reg~ do not secrete IL‐2, their high expression of CD25 allows them to consume and respond to low concentrations of exogenous IL‐2 [39](#cei12940-bib-0039){ref-type="ref"}, [40](#cei12940-bib-0040){ref-type="ref"}. CD4^+^CD25^--^CD127^+^ effector T cells express intermediate‐affinity IL‐2 receptors, IL‐2RB and IL‐2RG constitutively; thus, they require higher concentrations of IL‐2 for activation in the absence of T cell receptor (TCR) engagement [41](#cei12940-bib-0041){ref-type="ref"}. Importantly, we observed that applying VLDP of less than 5 IU/ml could enhance FoxP3 selectively in T~reg~ compared to CD8^+^, CD4^+^CD25^--^CD127^+/--^ and CD4^+^CD25^+^CD127^+^ effector T cells from the blood and liver of patients with AILD. There was no noticeable activation of these effector subsets based on expression of CD69, granzyme B or 2B4.

CTLA‐4 is an essential functional marker on T~reg~ [42](#cei12940-bib-0042){ref-type="ref"}. It functions by removing its co‐stimulatory ligands, CD80/CD86, from antigen‐presenting cells by transendocytosis [43](#cei12940-bib-0043){ref-type="ref"}. Mice deficient in CTLA‐4 display an autoimmune phenotype and immune dysregulation is observed in patients with CTLA‐4 polymorphisms [44](#cei12940-bib-0044){ref-type="ref"}. Our data suggest that VLDP up‐regulates CTLA‐4 expression by T~reg~, but has no impact on CD4^+^CD25^+^CD127^+^ effector T cells. Furthermore, we identify that CTLA‐4 is a significant mediator in the mechanisms by which VLDP confers enhanced suppressive potential to T~reg~; VLDP also maintains T~reg~ functional markers such as GITR and OX40.

We have reported recently that the inflamed liver microenvironment is deficient in IL‐2 protein and that activated intrahepatic T cells are the main source of IL‐2 in the human liver [4](#cei12940-bib-0004){ref-type="ref"}. Local consumption of IL‐2 by immune cells, including T~reg~, creates a microenvironment that is deficient in IL‐2 to the level that it is unable to support T~reg~ function. This finding is consistent with our previous observation that only some of the FoxP3^+^ T~reg~ in the liver undergo STAT‐5 phosphorylation [45](#cei12940-bib-0045){ref-type="ref"}. We observed that liver T~reg~ had higher baseline expressions of CTLA‐4, CD25 and FoxP3 than peripheral T~reg~ and these were equivalent to levels seen on peripheral blood T~reg~ after IL‐2 stimulation. A higher baseline expression probably reflects the more activated, effector state of liver *versus* blood lymphocytes. Liver T~reg~ also expressed higher levels of the TNF receptor superfamily members CD137, OX40 and GITR than peripheral T~reg~, and comparing our current data in peripheral blood with our previous phenotyping of intrahepatic T~reg~ in AILD we identify that CD69 (40%), LAG3 (20%), Tim3 (5%) and cytolytic granzyme B (5%) are also all up‐regulated on T~reg~ in the liver compared to periphery (\< 5% in peripheral blood) [4](#cei12940-bib-0004){ref-type="ref"}. This is in contrast to CD39 and PD‐1, which are expressed similarly on T~reg~ at both sites [4](#cei12940-bib-0004){ref-type="ref"}.

The effectiveness of T~reg~ function within the inflamed tissue setting might be compromised due to the action of inflammatory cytokines such as IL‐6, IL‐8, IL‐12, IFN‐γ and IL‐1βγ [4](#cei12940-bib-0004){ref-type="ref"}, which can enhance effector T cell activation and proliferation at the expense of T~reg~. Thus, exogenous IL‐2 such as VLDP might help to counteract these inflammatory signals [46](#cei12940-bib-0046){ref-type="ref"}, [47](#cei12940-bib-0047){ref-type="ref"}. CTLA‐4‐mediated T~reg~ suppressive function is via depletion of CD80/86 through transendocytosis [43](#cei12940-bib-0043){ref-type="ref"}. Excitingly, we observed that VLDP enhances T~reg~ suppressive function via CTLA‐4.

Recruitment of peripheral blood T~reg~ to the site of hepatic inflammation is dependent upon expression of the tissue‐homing CXCR3 chemokine receptor [45](#cei12940-bib-0045){ref-type="ref"}, [48](#cei12940-bib-0048){ref-type="ref"}, [49](#cei12940-bib-0049){ref-type="ref"}. We found expression of CXCR3 on approximately 50% of peripheral blood T~reg~ from AILD patients, comparable to controls, suggesting that cells from patients, even on immunosuppression, retain the liver‐homing receptors for recruitment. Moreover, we report that CXCR3 expression was unaffected by VLDP, implying that T~reg~ of patients on VLDP therapy would retain the capability to home to inflamed hepatic lobules and portal tracts. We have reported recently that human liver‐infiltrating T~reg~ are mainly of CD45RA^--^CCR7^--^ phenotype [4](#cei12940-bib-0004){ref-type="ref"}. Our findings now demonstrate that exogenous VLDIL‐2 up‐regulates T~reg~ functional markers predominantly in this effector (suppressor) population in all types of AILD. A recent study also described high expression of CXCR3 in CD4^+^ T cells in early‐stage PBC, which was associated with increased demethylation of the CXCR3 promoter. This up‐regulation was most striking in the activated memory CD45RO^+^ population [50](#cei12940-bib-0050){ref-type="ref"}. Taken together, these data suggest that CD4^+^ T~reg~ from patients with AILD will recruit to the human liver and be potentiated functionally by IL‐2 therapy.

T~reg~ depend upon IL‐2 for expansion and survival and cells undergo apoptosis upon IL‐2 deprivation [51](#cei12940-bib-0051){ref-type="ref"}. Bcl‐2 is a critical target in IL‐2 signalling [18](#cei12940-bib-0018){ref-type="ref"}, [52](#cei12940-bib-0052){ref-type="ref"}, helping to protect responding cells from apoptosis. A recent study also confirmed that use of a pan‐Bcl‐2 inhibitor leads to profound down‐regulation of FoxP3 and CTLA‐4 and a reduction in the suppressive function of T~reg~ [53](#cei12940-bib-0053){ref-type="ref"}. We demonstrated that VLDP enhances Bcl‐2 expression selectively in T~reg~ but not CD8^+^ T cells or CD4^+^ T effector cells from both peripheral blood and liver. This is an important observation because enhanced survival of immune‐regulatory T~reg~ is critical to the maintenance of tolerance.

In conclusion, our findings provide compelling evidence to support the design of T~reg~‐directed Phase I and II clinical trials administering VLDP as a cytokine monotherapy or in combination with autologous T~reg~ cell therapy in AILD. Given its short half‐life, regular doses of VLDP may be required to maintain efficacy.
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**Fig. S1.** Flow cytometry gating strategy for the analysis of signal transducer and activator of transcription‐5 (STAT‐5) expression by regulatory T cells (T~reg~) and eight other immune cell subsets.

**Fig. S2.** Very low dose interleukin (IL)−2 selectively up‐regulates signal transducer and activator of transcription‐5 (STAT‐5) in peripheral regulatory T cells (T~reg~) from autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) patient bloods. Peripheral blood mononuclear cells (PBMCs) from patients with AIH, PBC or primary sclerosing cholangitis (PSC) were stimulated for 10 min with IL‐2 (Proleukin) 0‐100 IU/ml and the percentage expression of phosphorylated (Y694)STAT5 by each leucocyte population assessed by flow cytometry at each IL‐2 dose. Data are mean ± standard error of the mean (s.e.m.) for five donors (AIH remission), four donors (AIH relapse) and three donors (PBC and PSC).

**Fig. S3.** Flow cytometry gating strategy (a) to define CD4, CD8 and regulatory T cell (T~reg~) populations and representative overlays (b,d) for markers of T cell activation and function on CD4, CD8 and T~reg~ in autoimmune liver disease (AILD) blood \[autoimmune hepatitis (AIH)\] and liver \[primary sclerosing cholangitis (PSC)\] following 18 h exposure to Proleukin 5 IU/ml.

**Fig. S4.** Effect of very low dose interleukin (IL)−2 on expression of IL‐2‐regulated regulatory T cell (T~reg~) functional markers CD25, cytotoxic T lymphocyte antigen‐4 (CTLA‐4) and forkhead box protein 3 (FoxP3^+^) by CD4, CD8 and T~reg~ cells from blood and liver. Peripheral blood mononuclear cells (PBMCs) from patients with autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) and liver infiltrating lymphocytes from autoimmune liver disease (AILD) livers were exposed to 0 or 5 IU/ml IL‐2 (Proleukin) for 18 h and the percentage expression of CD25, CTLA‐4 and FoxP3 by CD4^+^, CD8^+^ and T~reg~ cells examined by flow cytometry. Data are mean ± standard error of the mean (s.e.m.)for five donors (AIH), three donors (PSC) and five donors (liver).

**Fig. S5.** Sustained exposure to low dose interleukin (IL)−2 up‐regulates signal transducer and activator of transcription‐5 (STAT‐5) selectively in CD4^+^CD25^+^CD127^+^ T cells as well as in regulatory T cells (T~reg~). Peripheral blood mononuclear cells (PBMCs) from patients with autoimmune liver disease (AILD) were stimulated for 18 h with IL‐2 (Proleukin) doses of 0, 1, 5 and 10 IU/ml and expression of phosphorylated (Y694)STAT‐5 by each leucocyte population assessed by flow cytometry. (a) Percentage of each leucocyte population expressing pSTAT‐5 at each IL‐2 dose. (b) median fluorescence intensity (MFI) for pSTAT‐5.

**Fig. S6.** Effect of very low dose interleukin (IL)−2 on the suppressive ability of regulatory T cells (T~reg~) in autoimmune liver diseases. (a) CD4^+^CD25^--^ T responder cells were isolated from peripheral blood mononuclear cells (PBMCs) of controls (*n* = 3) and the effect of blocking CD28‐mediated co‐stimulation with Abatacept \[cytotoxic T lymphocyte antigen‐4‐immunoglobulin (CTLA‐4‐Ig)\] on division index at 5 days examined. (B) CD4^+^CD25^+^CD127^--^ T~reg~ and autologous CD4^+^CD25^--^ T responder cells were isolated from PBMC of two patients with autoimmune hepatitis (AIH) (one in remission and one in relapse). T responders were labelled with cell trace violet, and following overnight exposure of T~reg~ to 0 or 5 IU/ml Proleukin were co‐cultured with the T~reg~ in the presence of anti‐CD3 and dendritic cells, with or without CTLA‐4 blockade. Cell trace violet dilution indicating T responder cell division was analysed by flow cytometry at 5 days.
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